Veterinary Biomarkers Market Report 2026

Veterinary Biomarkers Market Overview

• Veterinary Biomarkers market size has reached to $0.91 billion in 2025 • Expected to grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: The Increasing Pet Ownership Propelling The Growth Of The Veterinary Biomarkers Market • Market Trend: Major Companies Collaborate To Enhance In-Clinic Diagnostic Capabilities And Improve Veterinary Patient Care • North America was the largest region in 2025.

The key promising market opportunities in the veterinary biomarkers market include: • Kits And Reagents (Segmentation By Product Type) → Expected gain of $0.36 Billion • Biomarkers (Segmentation By Product Type) → Expected gain of $0.24 Billion • Biomarker Readers (Segmentation By Product Type) → Expected gain of $0.09 Billion

What Is Covered Under Veterinary Biomarkers Market?

Veterinary biomarkers are measurable indicators used to diagnose, monitor, and manage diseases in animals. They can be biological molecules, such as proteins, genes, or metabolites, which reflect a specific physiological or pathological state. These biomarkers aid in early disease detection, treatment evaluation, and understanding of disease mechanisms. The main product types of veterinary biomarkers are biomarkers, kits and reagents, and biomarker readers. Biomarkers refer to specific biological molecules or substances used to detect, diagnose, and monitor health conditions in animals. These biomarkers, found in blood, urine, or other body fluids, provide crucial information about an animal’s health status. Various disease types include inflammatory and infectious diseases, cardiovascular diseases, skeletal muscle diseases, tumors, and others, and are used on a variety of animals, including companion animals and production animals. These biomarkers find application in disease diagnostics, preclinical research, and others.

What Is The Veterinary Biomarkers Market Growth Forecast?

The veterinary biomarkers market size is expected to see rapid growth in the next few years. It will grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to advancement in biomarker discovery, increasing investment in veterinary diagnostics, rising awareness of animal health monitoring, growth of companion and production animal segments, adoption of automated biomarker readers and digital platforms. Major trends in the forecast period include expansion of diagnostic biomarker development, growth in predictive and prognostic biomarker applications, increasing adoption of elisa, pcr, and rapid test kits, rising use of advanced biomarker readers and analytical devices, growing focus on companion and production animal health.

What Is The Driver Of The Veterinary Biomarkers Market?

The increasing pet ownership is expected to propel the growth of the veterinary biomarkers market going forward. Pet ownership is the state of having one or more animals as companions, where a person provides care, shelter, and attention to meet the animals’ needs and well-being. The rise in pet ownership can be attributed to several factors, including the desire for companionship, the benefits of pet therapy, and the growing awareness of the positive impact pets have on mental and physical well-being. Veterinary biomarkers are used in pet ownership to monitor animal health, enabling early disease detection and personalized treatment plans. For instance, in June 2025, according to the Petfood Industry, a US-based organization, 94 million U.S. households owned at least one pet, up from 82 million in 2023, reflecting a significant increase in pet ownership and rising demand for pet care products and services. Therefore, the increasing pet ownership is driving the growth of the veterinary biomarkers industry.

How Will The Drivers Impact Growth In The Global Veterinary Biomarkers Market?

• Integration Of AI-Driven In-Clinic Diagnostic Ecosystems (High) – During the forecast period, the integration of AI-driven in-clinic diagnostic ecosystems is expected to become a key growth driver for the veterinary biomarkers market by 2030. Veterinary clinics are increasingly adopting artificial intelligence-enabled diagnostic platforms that combine biomarker analysis with real-time data interpretation to improve diagnostic speed and accuracy. These systems enable veterinarians to process complex biomarker data efficiently, supporting early-stage disease identification and treatment planning. The shift toward point-of-care diagnostics integrated with AI tools is also enhancing workflow efficiency and reducing dependency on centralized laboratories. As veterinary practices continue to digitize and modernize diagnostic capabilities, demand for biomarker-based solutions is expected to rise significantly. • Surge In Prevalence Of Chronic Age-Related Canine And Feline Diseases (High) – During the forecast period, the surge in prevalence of chronic age-related canine and feline diseases is expected to emerge as a major factor driving the expansion of the veterinary biomarkers market by 2030. Aging pet populations are increasingly affected by long-term conditions such as renal disorders, diabetes, and arthritis, creating a sustained need for continuous health monitoring solutions. Biomarkers play a critical role in tracking disease progression, assessing treatment response, and enabling timely medical interventions in such conditions. The growing lifespan of companion animals is further amplifying the need for advanced diagnostic tools that support long-term care management. • Expansion Of Onco-Fertility And Precision Medicine In Companion Animals (Medium) – During the forecast period, the expansion of onco-fertility and precision medicine in companion animals is expected to act as a key growth catalyst for the veterinary biomarkers market by 2030. Advances in veterinary oncology are enabling more targeted treatment approaches, where biomarkers are used to identify specific tumor characteristics and guide therapy selection. Additionally, the emergence of onco-fertility practices is driving the need for specialized biomarker testing to preserve reproductive health while managing cancer treatments in animals. The increasing focus on individualized treatment protocols is encouraging the development of highly specific and sensitive biomarker assays. As precision medicine gains traction in veterinary care, the adoption of biomarker-based diagnostics is expected to accelerate.

How Will The Restraints Impact Growth In The Global Veterinary Biomarkers Market?

• High Capital Expenditure and Consumable Costs for Specialized Testing (High) – During the forecast period, high capital expenditure and consumable costs for specialized testing are restricting the growth of the veterinary biomarkers market. Expensive diagnostic instruments, reagents, and ongoing testing costs are increasing financial burden on veterinary clinics and laboratories, thereby limiting widespread adoption • Complexity of Species-Specific Validation and Regulatory Hurdles (High) – During the forecast period, complexity of species-specific validation and regulatory hurdles is restricting the growth of the veterinary biomarkers market. Variability across animal species and stringent regulatory requirements for validation are creating challenges in standardization and delaying product approvals • Limited Awareness And Adoption Among Veterinary Practitioners (Medium) – During the forecast period, limited awareness and adoption among veterinary practitioners is restricting the growth of the veterinary biomarkers market. Lack of familiarity with advanced biomarker-based diagnostics and preference for conventional testing methods are slowing market penetration

Key Players In The Global Veterinary Biomarkers Market

Major companies operating in the veterinary biomarkers market are Thermo Fisher Scientific Inc., Zoetis Inc., IDEXX Laboratories Inc., Antech Diagnostics Inc., Neogen Corporation, Heska Corporation, Olink Proteomics, SomaLogic, Life Diagnostics Inc., INDICAL BIOSCIENCE GmbH., Mercodia AB, Bionote USA Inc., Acuvet Biotech, Alertix Veterinary Diagnostics AB., MI:RNA Diagnostics Ltd., Veterinary Biomarkers Inc., Vetmaya Healthcare Private Limited, VolitionRx, BioVet Diagnostics, Randox Laboratories Ltd., Bio‑Rad Laboratories Inc., QIAGEN N.V., FidoCure, Scil Animal Care Company GmbH, Shenzhen Mindray Animal Medical Technology Co. Ltd., Esaote SPA, Innovative Diagnostics SAS, Ayoxxa Biosystems

Global Veterinary Biomarkers Market Trends and Insights

Major companies operating in the veterinary biomarkers market are focused on forming strategic partnerships to gain a competitive edge in the market. Strategic partnerships in the veterinary biomarkers field involve collaborations between companies, research institutions, and veterinary practices to advance the development and application of diagnostic tools. For instance, in November 2025, Bionote USA, a US-based veterinary diagnostics company, launched the Vcheck C1 In-Clinic Chemistry Analyzer, an affordable, compact biochemistry testing device designed to expand point-of-care biomarker and diagnostic capabilities for veterinary practices. The Vcheck C1 enables simultaneous analysis of up to 24 biochemical parameters from small animal samples in 10–12 minutes, delivering laboratory-grade accuracy with a simple workflow. It supports testing across 34 species, including canine, feline, equine, and bovine patients, with validated reference ranges for each species. Featuring broad test panels such as comprehensive chemistry, electrolyte, liver, kidney, and diabetes profiles, the analyzer helps clinicians quickly diagnose and monitor health conditions without sending samples to external labs. The product’s affordable pricing and multi-species support aim to enhance access to rapid, in-clinic biomarker diagnostics for a wide range of veterinary settings.

What Are Latest Mergers And Acquisitions In The Veterinary Biomarkers Market?

In November 2025, Zoetis Inc., a US-based provider of animal health medicines, vaccines, diagnostics, and technology solutions, acquired Veterinary Pathology Group (VPG) for undisclosed amount. With this acquisition, Zoetis aimed to expand its veterinary diagnostics portfolio, enhancing its ability to provide advanced biomarker and pathology testing solutions to veterinarians in the UK and Ireland and strengthen its global diagnostic footprint. Veterinary Pathology Group is a UK and Ireland based provider of comprehensive laboratory diagnostic services supporting biomarker-based testing for disease detection and monitoring in animal health.

What Defines the Veterinary Biomarkers Market?

The veterinary biomarkers market consists of sales of biomarker research tools, imaging biomarkers, diagnostic kits, and immunoassays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Veterinary Biomarkers Market Report 2026?

The veterinary biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.